Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
Table 5
Least-squares mean change from baseline to Week 24 (Visit 12) in the efficacy measures.
Measure
Double-blind treatment phase
valuea
Pomaglumetad methionil ()
Aripiprazole ()
LS mean difference between pomaglumetad methionil and aripiprazole (SE)
Baseline mean (SD)
Δ to Week 24 (Visit 12) LS mean (SE)
Baseline mean (SD)
Δ to Week 24 (Visit 12) LS mean (SE)
PANSS
Total score
77.9 (24.15)
−12.03 (0.99)
79.5 (22.19)
−15.58 (1.58)
3.55 (1.77)
0.045*
Positive
19.1 (6.75)
−3.40 (0.32)
19.5 (6.31)
−4.62 (0.50)
1.21 (0.56)
0.032*
Negative
20.4 (7.13)
−2.98 (0.31)
21.2 (7.10)
−3.34 (0.48)
0.36 (0.54)
0.509
General psychopathology
38.4 (13.08)
−5.80 (0.56)
38.7 (12.10)
−7.85 (0.89)
2.05 (1.00)
0.040*
CGI-S score
4.1 (0.79)
−0.51 (0.05)
4.1 (0.74)
−0.69 (0.08)
0.17 (0.09)
0.055
NSA-16 total score
46.3 (13.34)
−6.22 (0.68)
47.5 (13.48)
−6.37 (1.03)
0.15 (1.11)
0.891
. values are from type III tests of LS mean differences between treatments at each visit from MMRM. Δ: change from baseline; LS mean: least-squares mean; : number of patients; CGI-S: Clinical Global Impression-Severity; MMRM: mixed-effects model with repeated measures; NSA-16: 16-Item Negative Symptom Assessment; PANSS: Positive and Negative Syndrome Scale; SD: standard deviations; SE: standard error.
